Johnson & Johnson and 4 Other Biopharmaceutical Stocks That Might Be Ready to Break Out
Biopharmaceutical stocks that have lagged behind the broader market may finally have their day in the sun. BofA Securities ...
ジャパンタイムズ4h
Gilead's Japan head says nation can be among first to end HIV epidemic
The pharmaceutical powerhouse has two drugs that disrupt the transmission of the virus, one of which has been approved for ...
Wells Fargo Reaffirms Their Buy Rating on Gilead Sciences (GILD)
Wells Fargo analyst Mohit Bansal maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $140.00.
Bank of America Securities Remains a Buy on Gilead Sciences (GILD)
In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Gilead Sciences (GILD – Research Report), ...
Le Lézard10h
XPOVIO Continues to Disrupt the Oncology Market with Expanded Indications and Strong Market Performance | DelveInsight
DelveInsight's "XPOVIO Market Size, Forecast, and Market Insight Report" highlights the details around XPOVIO, a first-in-class, oral selective inhibitor of nuclear export (SINE) ...
Med Device Online21h
Lessons Learned From Vivani Medical's Study Of GLP-1 Implant
Vivani Medical Cofounder and CEO Adam Mendelsohn, Ph.D. discusses the company’s first application of the NanoPortal, ...
Shaping the future of healthcare analytics: Nidhi Shashikumar's data-driven Impact
With over seven years of experience in data science and analytics, Nidhi has led high-impact projects at leading healthcare ...